Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.
Eli Lilly and Company announced earlier this week that its popular obesity drug, Zepbound (tirzepatide) outperformed rival ...
It didn’t take long for the shine to come off one of biotech’s recent IPO success stories, with BioAge Labs scrapping a phase ...
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
The foreign ministry of Russia, a longtime ally, did not provide details on where President Bashar al-Assad had gone. Rebels stormed the Syrian capital on Sunday without encountering any ...
Jupiter at Opposition This Weekend: Here's the Best Time to See It ...